Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1976 Apr;3(2):243–249. doi: 10.1111/j.1365-2125.1976.tb00599.x

A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol.

R A Branch, J James, A E Read
PMCID: PMC1428884  PMID: 973958

Abstract

The pharmacokinetics, following i.v. administration of (+)-propranolol (40 mg) have been compared to in vitro measurement of protein binding and biochemical parameters of liver function in six normal subjects and twenty patients with stable chronic liver disease. The clearance of (+)-propranolol decreased with evidence of increasing severity of impairment of liver function correlating significantly with a fall in serum albumin, a rise in bilirubin and a prolongation in prothrombin index. The clearance of (+)-propranolol correlated with and was numerically similar to the clearance of indocyanine green in normal subjects and also in patients with chronic liver disease. Protein binding was decreased in chronic liver disease, but this change was not related to changes in plasma proteins. In normal subjects and patients without ascites the volume of distribution increased with decreases in protein binding. Ascites was associated with a further increase in the volume of distribution. The considerable variation in half-life largely depends on changes in liver blood flow, the degree of protein binding and the plasma protein pool size.

Full text

PDF
249

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acocella G., Bonollo L., Garimoldi M., Mainardi M., Tenconi L. T., Nicolis F. B. Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease. Gut. 1972 Jan;13(1):47–53. doi: 10.1136/gut.13.1.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Branch R. A., Herbert C. M., Read A. E. Determinants of serum antipyrine half-lives in patients with liver disease. Gut. 1973 Jul;14(7):569–573. doi: 10.1136/gut.14.7.569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. CAESAR J., SHALDON S., CHIANDUSSI L., GUEVARA L., SHERLOCK S. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci. 1961 Aug;21:43–57. [PubMed] [Google Scholar]
  4. CHERRICK G. R., STEIN S. W., LEEVY C. M., DAVIDSON C. S. Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction. J Clin Invest. 1960 Apr;39:592–600. doi: 10.1172/JCI104072. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Evans G. H., Nies A. S., Shand D. G. The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J Pharmacol Exp Ther. 1973 Jul;186(1):114–122. [PubMed] [Google Scholar]
  6. Evans G. H., Shand D. G. Disposition of propranolol. VI. Independent variation in steady-state circulating drug concentrations and half-life as a result of plasma drug binding in man. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):494–500. doi: 10.1002/cpt1973144part1494. [DOI] [PubMed] [Google Scholar]
  7. George C. F., Fenyvesi T., Conolly M. E., Dollery C. T. Pharmacokinetics of dextro-, laevo- and racemic propranolol in man. Eur J Clin Pharmacol. 1972 Mar;4(2):74–76. doi: 10.1007/BF00562500. [DOI] [PubMed] [Google Scholar]
  8. Hoffman T. A., Cestero R., Bullock W. E. Pharmacodynamics of carbenicillin in hepatic and renal failure. Ann Intern Med. 1970 Aug;73(2):173–178. doi: 10.7326/0003-4819-73-2-173. [DOI] [PubMed] [Google Scholar]
  9. KUNIN C. M., GLAZKO A. J., FINLAND M. Persistence of antibiotics in blood of patients with acute renal failure. II. Chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis. J Clin Invest. 1959 Sep;38:1498–1508. doi: 10.1172/JCI103928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Levi A. J., Sherlock S., Walker D. Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet. 1968 Jun 15;1(7555):1275–1279. doi: 10.1016/s0140-6736(68)92292-7. [DOI] [PubMed] [Google Scholar]
  11. Mawer G. E., Miller N. E., Turnberg L. A. Metabolism of amylobarbitone in patients with chronic liver disease. Br J Pharmacol. 1972 Mar;44(3):549–560. doi: 10.1111/j.1476-5381.1972.tb07292.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Nies A. S., Evans G. H., Shand D. G. Regional hemodynamic effects of beta-adrenergic blockade with propranolol in the unanesthetized primate. Am Heart J. 1973 Jan;85(1):97–102. doi: 10.1016/0002-8703(73)90531-0. [DOI] [PubMed] [Google Scholar]
  13. REDEKER A. G., GELLER H. M., REYNOLDS T. B. Hepatic wedge pressure, blood flow, vascular resistance and oxygen consumption in cirrhosis before and after end-to-side portacaval shunt. J Clin Invest. 1958 Apr;37(4):606–618. doi: 10.1172/JCI103643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. REDEKER A. G., KUNELIS C. T., YAMAMOTO S., REYNOLDS T. B. ASSESSMENT OF PORTAL AND HEPATIC HEMODYNAMICS AFTER SIDE-TO-SIDE PORTACAVAL SHUNT IN PATIENTS WITH CIRRHOSIS. J Clin Invest. 1964 Jul;43:1464–1471. doi: 10.1172/JCI105022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Riegelman S., Loo J. C., Rowland M. Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. J Pharm Sci. 1968 Jan;57(1):117–123. doi: 10.1002/jps.2600570123. [DOI] [PubMed] [Google Scholar]
  16. Rowland M., Benet L. Z., Graham G. G. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm. 1973 Apr;1(2):123–136. doi: 10.1007/BF01059626. [DOI] [PubMed] [Google Scholar]
  17. Shand D. G., Nuckolls E. M., Oates J. A. Plasma propranolol levels in adults with observations in four children. Clin Pharmacol Ther. 1970 Jan-Feb;11(1):112–120. doi: 10.1002/cpt1970111112. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES